Axel Hoos, GSK: Focusing on immuno-oncology and cancer epigenetics




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Axel Hoos, GSK: Focusing on immuno-oncology and cancer epigenetics
Released on: January 29, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    GSK has had a recent change in Oncology after recently divesting their marketed oncology products to Novartis whilst retaining their R&D pipeline.
  • Summary
  • Transcript
  • Company
GSK has had a recent change in Oncology after recently divesting their marketed oncology products to Novartis whilst retaining their R&D pipeline. During BIO 2015, Axel Hoos, VP Oncology R&D at GSK explained to Fintan Walton, CEO of PharmaVentures what these changes will mean and how they are now focussing on two areas of cutting edge science.
GSK has had a recent change in Oncology after recently divesting their marketed oncology products to Novartis whilst retaining their R&D pipeline. During BIO 2015, Axel Hoos, VP Oncology R&D at GSK explained to Fintan Walton, CEO of PharmaVentures what these changes will mean and how they are now focussing on two areas of cutting edge science.
GlaxoSmithKline (GSK)
GSK is the world's second largest pharmaceutical company, by employees; and a research-based company with a wide portfolio of pharmaceutical products covering anti-infectives, central nervous system, respiratory, gastro-intestinal/metabolic, oncology, and vaccines products. It also has a Consumer Healthcare operation comprising leading oral healthcare products, nutritional drinks, and over the counter medicines.